The phase II PEMBRO-RT trial demonstrated that SBRT combined with pembrolizumab doubled objective response rates (ORR) in PD-L1-negative NSCLC compared to ICI monotherapy (13). The gene discussed is CD274; the disease is non-small cell lung carcinoma.